The Initial Public Offer of Gland Pharma was oversubscribed by 2.05 times, on the closing day of the public issue.
The issue, which was opened for public on November 9 and ended on Wednesday, is expected to fetch Rs 6,480 crore.
The IPO comprises a fresh issue of shares worth up to Rs 1,250 crore and an offer for sale of 3,48,63,635 shares.
The price range for the offer has been fixed at Rs 1,490-1,500 per share and Gland Pharma raised Rs 1943.86 crore from anchor investors who were allotted12,959,089 equity shares at the upper price band of Rs 1,500 per equity shares.
As many as 70 marquee global and domestic funds came in as anchor investors, the company said in a release.
Gland Pharma will use Rs 1,250 crore fresh funds for capital expenditureand working capital requirements.
The company’s promoters are Fosun Singapore and Shanghai Fosun Pharma.
Gland Pharma was founded by P V N Raju in 1978 and Fosun Pharma acquired 74 per cent stake in the company in 2017.
